Leukaemia: a model metastatic disease

AE Whiteley, TT Price, G Cantelli, DA Sipkins - Nature Reviews Cancer, 2021 - nature.com
In contrast to solid cancers, which often require genetic modifications and complex cellular
reprogramming for effective metastatic dissemination, leukaemic cells uniquely possess the …

[PDF][PDF] Targeting cancer stemness in the clinic: from hype to hope

C Saygin, D Matei, R Majeti, O Reizes, JD Lathia - Cell stem cell, 2019 - cell.com
Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

D Vetrie, GV Helgason, M Copland - Nature Reviews Cancer, 2020 - nature.com
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance

R Alves, AC Gonçalves, S Rutella, AM Almeida… - Cancers, 2021 - mdpi.com
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Third-line therapy for chronic myeloid leukemia: current status and future directions

J Cortes, F Lang - Journal of Hematology & Oncology, 2021 - Springer
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation

GM Burslem, AR Schultz, DP Bondeson, CA Eide… - Cancer research, 2019 - AACR
Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …

Cancer stem cells—key players in tumor relapse

M Marzagalli, F Fontana, M Raimondi, P Limonta - Cancers, 2021 - mdpi.com
Simple Summary Cancer is one of the hardest pathologies to fight, being one of the main
causes of death worldwide despite the constant development of novel therapeutic strategies …

[HTML][HTML] Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells

M Carlsten, M Järås - Frontiers in immunology, 2019 - frontiersin.org
Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …